Comparing Efficacy Between Anti-microtubule and Non-anti-microtubule as 3th Therapy After 2nd Line EGFR-TKI Therapy
|The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.|
|ClinicalTrials.gov Identifier: NCT00836160|
Recruitment Status : Completed
First Posted : February 4, 2009
Last Update Posted : September 20, 2012
This is an observational prospective study that investigates only daily practice. The prescription of anti-cancer medicine is separated from the decision to include the patient in this study. In addition, the assignment of the patient to a particular therapy or therapeutic strategy is not decided in advance by this study protocol, but falls within current practice.
The patient who fulfils eligible criteria will be enrolled when starts to receive the second-line EGFR-TKI therapy. The frequency of tumor response evaluation by RECIST criteria follows the investigator's discretion as daily practice.
|Condition or disease|
|Study Type :||Observational|
|Actual Enrollment :||36 participants|
|Official Title:||Comparing Efficacy Between Anti-microtubule and Non-anti-microtubule as 3th Therapy After 2nd Line EGFR-TKI Therapy|
|Study Start Date :||August 2009|
|Actual Primary Completion Date :||September 2012|
|Actual Study Completion Date :||September 2012|
- PFS of the third-line therapy [ Time Frame: 9 months ]
- Overall objective tumor response (complete response [CR] + partial response [PR]) of the third-line therapy by RECIST criteria [ Time Frame: 9 months ]
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT00836160
|Gueishan Township, Taiwan|